IndustryCompany release

UCB and Cradle partner on AI protein design for antibody discovery

UCB · Wed 04 Nov 2026

UCB will use Cradle's AI-driven protein engineering platform in selected discovery projects, from hit generation to preclinical readiness, with no financial terms disclosed.

UCB and Cradle, a company focused on AI-driven protein engineering, announced a strategic collaboration on 4 November 2026. Under the agreement, UCB will apply Cradle's platform in selected discovery projects.

The work is set to span several early stages of development: hit generation, lead optimisation and preclinical readiness. The stated aim is to accelerate the identification of antibody candidates intended for severe diseases.

The companies did not disclose financial terms. The summary of the announcement available to VigiEye does not name the target diseases or specific programmes, give a timeline, or say how many projects are covered.

What it means for your team

  • The collaboration is confined to discovery and preclinical stages, so no direct regulatory filing or pharmacovigilance implications arise at this point.
  • Teams tracking AI use in biologics development may wish to watch how computational design tools are documented as candidates move towards clinical development.
  • Commercial terms, programme scope and target indications were not disclosed, so market-access impact cannot yet be assessed.

Company's press release: UCB ↗

Article written by VigiEye from the official source (UCB). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →